Jay Bhaumik sees drug pricing transparency as one of the defining healthcare challenges of 2026. As prescription costs continue to rise and patients assume more direct financial responsibility through high-deductible plans and increased cost-sharing, pricing opacity has shifted from a back-office concern to a front-line healthcare issue.
For providers, payers, pharmacies, and pharmaceutical companies alike, the ability to clearly understand how drug costs are structured now directly influences adherence, outcomes, and trust.
With more than two decades of leadership in pharmaceutical operations, healthcare technology, and compliance strategy, Bhaumik brings a uniquely systems-level perspective to the issue. Chairman of Thesis Pharmacy, he is a leader who has built multiple healthcare ventures, and his experience spans pharmacy operations, innovation, strategic growth, and healthcare data systems.
In this Q&A, Jay Bhaumik shares his perspective on why drug pricing transparency has become urgent, where the current system remains most opaque, and what solutions are beginning to reshape the industry.
Q&A With Jay Bhaumik
Q
Why has drug pricing transparency become such an important issue right now?
A
Drug pricing transparency has become increasingly urgent because several economic and regulatory pressures have converged at the same time. Rising healthcare costs continue to place a strain on employers, insurers, and patients, while prescription drug spending, particularly in specialty medications and biologics, has outpaced broader inflation trends
At the patient level, the shift toward high-deductible health plans means individuals are far more directly exposed to pricing variability than in previous years. What was once largely absorbed by employers or insurers now becomes an immediate financial burden for families making care decisions.
At the same time, policymakers, employers, and healthcare organizations are demanding greater accountability around how prices are set. In 2026, transparency requires restoring predictability and trust in a market where cost directly affects access to treatment.
Q
What are the biggest factors contributing to the complexity of prescription drug pricing?
A
The complexity stems from the fact that prescription drug pricing operates across a deeply layered supply chain. Manufacturers, wholesalers, pharmacies, payers, and pharmacy benefit managers all influence the final cost, often through mechanisms that are not visible to either providers or patients.
A driving factor in this complexity is the widespread use of rebates and retrospective pricing structures, which can significantly alter the net cost of a drug long after the initial transaction. Another factor is the use of multiple pricing benchmarks, each of which serves a different purpose in reimbursement and contracting.
Formulary placement also plays a major role, since drugs may be preferred or excluded based on negotiated rebate structures rather than purely clinical considerations. Site-of-care differences, whether a drug is dispensed through retail or specialty.
Q
How have recent policy discussions and regulatory efforts shaped the transparency movement?
A
Recent policy efforts have significantly elevated transparency as a national healthcare priority. One of the most consequential developments has been Medicare drug price negotiation provisions introduced under the Inflation Reduction Act, which have brought pricing discussions into sharper public focus.
At the same time, PBM reform proposals aimed at spreading pricing, rebate disclosure, and fiduciary accountability have accelerated discussions around market transparency. State-level disclosure laws and CMS transparency rules for hospitals and payers have also contributed to greater visibility.
Visibility alone, however, does not necessarily translate into usability. One of the ongoing challenges is that data remains fragmented across formats and systems. Even where information is technically disclosed, inconsistent reporting standards and enforcement gaps limit its practical value for clinicians, employers, and patients.
Q
What are the biggest challenges healthcare organizations face in improving pricing transparency?
A
The largest challenge is fragmentation. Pricing data often sits across disconnected systems managed by pharmacies, payers, PBMs, providers, and manufacturers, making real-time visibility difficult.
Healthcare organizations also face contractual confidentiality clauses that restrict how much information can be shared externally. In many cases, even internal teams struggle to gain a complete picture of acquisition cost, reimbursement, and patient responsibility.
There is also the issue of misaligned incentives. Rebate-driven models may reward volume or formulary preference structures that do not necessarily align with transparency goals.
Operationally, generating accurate real-time price calculations is resource-intensive. Without standardized pricing definitions across the industry, even well-intentioned transparency initiatives can produce confusion rather than clarity.
Most importantly, organizations often struggle to translate pricing data into actionable insights that help clinicians make better prescribing decisions at the point of care.
Q
How do PBMs influence drug pricing and transparency in the current system?
A
PBMs sit at the center of the modern prescription drug ecosystem. They negotiate rebates with manufacturers, determine formulary placement, and manage reimbursement structures for pharmacies. Because of this position, they have substantial influence over both drug utilization and net pricing.
The challenge is that many PBM business models still rely on opaque revenue mechanisms, including spread pricing and retained rebates. These structures can limit visibility into the true cost of medications and obscure how much savings is actually passed through to employers or patients.
This lack of transparency creates uncertainty across the supply chain and often makes it difficult for stakeholders to understand where cost inflation is occurring.
Q
What role can technology and data analytics play in improving visibility into drug costs?
A
Technology is one of the most promising solutions in this space. Real-time benefit verification at the point of prescribing is already helping providers understand coverage, prior authorization requirements, and estimated patient out-of-pocket costs before therapy is initiated.
Advanced analytics and AI can also help optimize prescribing by identifying lower-cost therapeutic alternatives, reimbursement risks, and sourcing inefficiencies. Integrated dashboards that connect acquisition cost, reimbursement, margin, and patient responsibility are becoming increasingly valuable for pharmacy operations and health systems.
There is also growing interest in blockchain and distributed ledger models for creating more auditable transaction pathways. The real opportunity lies in turning raw pricing data into decision-ready intelligence that supports both clinical and financial outcomes.
Q
How does the lack of pricing transparency affect patients and providers daily?
A
For patients, the impact is immediate and deeply practical. Unexpected out-of-pocket costs can lead to therapy abandonment, delays in treatment initiation, and long-term non-adherence.
In many cases, patients discover affordability barriers only after a prescription has already been written, which introduces frustration and delays in care. For providers, opacity creates prescribing uncertainty. Clinicians may select a clinically appropriate therapy only to later learn that the medication is financially inaccessible.
This also increases administrative burden through appeals, prior authorizations, and medication changes. Ultimately, lack of transparency erodes trust across the care experience.
Q
Are there promising solutions or models emerging to improve clarity and predictability?
A
Yes, several promising models are gaining traction. Pass-through PBM structures that fully disclose rebates and administrative fees are attracting growing attention. Pharmacy self-pay models, which use transparent markup structures, are also helping simplify pricing conversations. A pharmacist recommending a cheaper alternative like generic medication is key to reducing medication costs.
Direct-to-employer contracting is another emerging model that reduces intermediaries and creates clearer cost structures. Value-based pricing tied to outcomes is particularly promising for specialty and high-cost therapies, as it aligns reimbursement with clinical performance.
Q
What responsibilities do pharmaceutical companies, pharmacies, and providers each have?
A
Each stakeholder has a distinct responsibility. Pharmaceutical companies must provide clearer rationale for pricing decisions and reduce overreliance on opaque rebate structures. Pharmacies should prioritize visibility into acquisition cost, reimbursement pathways, and patient affordability support.
Providers have a responsibility to integrate cost awareness into prescribing decisions whenever possible, particularly as technology tools improve point-of-care visibility. Improving transparency will require collaboration across the entire ecosystem rather than isolated reform within a single stakeholder group.
Follow Jay Bhaumik’s Journey
About Jay
Jay Bhaumik is a pharmaceutical executive, entrepreneur, and healthcare innovator with more than 20 years of leadership experience across pharmacy operations, healthcare technology, and compliance strategy. As Chairman of Thesis Pharmacy, he has helped lead the company to national recognition, including being named by Inc. Magazine among the fastest-growing healthcare companies in the United States and earning distinction as one of the nation’s top compounding pharmacies.
His expertise spans product strategy, operational excellence, sales transformation, and regulatory compliance, with a strong emphasis on innovation and customized patient solutions. In addition to his work in pharmacy, Bhaumik has successfully led healthcare cybersecurity and healthcare IT ventures through successful exits. He holds a Doctor of Pharmacy degree, a postdoctoral fellowship, a master’s in information systems, and an MBA from MIT.
